ArticleMolecular and cellular biology1993
Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells.
Article in Molecular and cellular biology, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 152 citations in OpenAlex.
- Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.Cancer · 2012Trial
- PDGF/PDGFR axis in the neural systems.Molecular aspects of medicine · 2018Review
- PDGFR inhibition mediated intracellular signalling in C6 glioma growth and migration: role of ERK and ROCK pathway.Cytotechnology · 2018Article
- FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells.Cancer research · 2015Article
- Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Autocrine PDGF stimulation in malignancies.Upsala journal of medical sciences · 2012Review
- Post-transcriptional regulation of PDGFα-receptor in O-2A progenitor cells.International journal of clinical and experimental medicine · 2011Article
- Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.Neuro-oncology · 2009Article
- Growth factor receptors signaling in glioblastoma cells: therapeutic implications.Journal of neuro-oncology · 2009Article
- Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins.The Journal of clinical investigation · 2008Article
- NF-kappaB controls growth of glioblastomas/astrocytomas.Molecular and cellular biochemistry · 2008Article
- Characterization of an imatinib-sensitive subset of high-grade human glioma cultures.Oncogene · 2006Article
- Autocrine PDGFR signaling promotes mammary cancer metastasis.The Journal of clinical investigation · 2006Article
- Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas.Proceedings of the National Academy of Sciences of the United States of America · 2005Article
- Neural development and the ontogeny of central nervous system tumors.Neuron glia biology · 2004Article
- Engineering of tooth-supporting structures by delivery of PDGF gene therapy vectors.Molecular therapy : the journal of the American Society of Gene Therapy · 2004Article
- Inhibition of platelet-derived growth factor signalling induces autophagy in malignant glioma cells.British journal of cancer · 2004Article
- Effect of sustained gene delivery of platelet-derived growth factor or its antagonist (PDGF-1308) on tissue-engineered cementum.Journal of periodontology · 2004Article
- Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis.The American journal of pathology · 2002Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Malignant astrocytoma is the most common primary human brain tumor. Most astrocytomas express a combination of platelet-derived growth factor (PDGF) and PDGF receptor which could close an autocrine loop. It is not known whether these autocrine loops contribute to the transformed phenotype of astrocytoma cells or are incidental to that phenotype. Here we show that dominant-negative mutants of the PDGF ligand break the autocrine loop and revert the phenotype of BALB/c 3T3 cells transformed by the PDGF-A or PDGF-B (c-sis) gene. Then, we show that these mutants are selective in that they do not alter the phenotype of 3T3 cells transformed by an activated Ha-ras or v-src gene or by simian virus 40. Finally, we show that these mutants revert the transformed phenotype of two independent human astrocytoma cell lines. They have no effect on the growth of human medulloblastoma, bladder carcinoma, or colon carcinoma cell lines. These observations are consistent with the view that PDGF autocrine loops contribute to the transformed phenotype of at least some human astrocytomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.